title: Serum resistin and high sensitive CRP levels in patients with subclinical hypothyroidism before and after L-thyroxine therapy.
abstract: BACKGROUND
  Subclinical hypothyroidism (SH) is defined by increased thyrotropin (TSH) and normal free thyroxine (fT4) and free triiodothyronine (fT3) levels. Resistin is secreted from adipose tissue and is reported to be associated with insulin resistance and/or inflammation. High sensitive CRP (hs-CRP) is a reliable marker of inflammation. Data related to levels of resistin and hs-CRP in SH and the effect of L-thyroxine treatment on those is limited. We aimed to determine the levels of resistin and hs-CRP in women with SH, and potential effects of L-thyroxine therapy on those levels.
  
  
  METHODS
  Thirty-six patients with SH and 27 age- and BMI-matched healthy control women were included. Waist circumference (Wc), waist-to-hip ratio (WHR), resting energy expenditure (REE), fat mass (FM) and lean mass (LM), TSH, free T4 (fT4), free T3 (fT3), total cholesterol (TC), triglycerides (TG), and HDL- and LDL-cholesterol were determined in all participants. Patients received L-thyroxine treatment for 6 months, after which all measurements were repeated. Resistin and hs-CRP levels were studied from frozen samples after the completion of the study.
  
  
  RESULTS
  The 2 groups had similar values for Wc, WHR, FM, LM, TC, TG, HDL-C, LDL-C, resistin, and hs-CRP at the beginning. fT4 were higher, whereas TSH was lower in the control group. Resistin and hs-CRP levels did not change after treatment. hs-CRP correlated with BMI and FM before and after treatment.
  
  
  CONCLUSIONS
  Our results suggest that achievement of euthyroid status by replacement therapy did not change resistin or hs-CRP levels in women with SH. hs-CRP correlated with parameters of obesity, which emphasizes the role of body weight in inflammation.
authors.affiliation: Etlik Ihtisas Research and Training Hospital, Department of Endocrinology and Metabolism, Etlik, Ankara, Turkey. duyguyaks@yahoo.com
authors.forename: Duygu Yazgan
authors.initials: DY
authors.lastname: Aksoy
authors.forename: Nese
authors.initials: N
authors.lastname: Cinar
authors.forename: Ayla
authors.initials: A
authors.lastname: Harmanci
authors.forename: Jale
authors.initials: J
authors.lastname: Karakaya
authors.forename: Bulent Okan
authors.initials: BO
authors.lastname: Yildiz
authors.forename: Aydan
authors.initials: A
authors.lastname: Usman
authors.forename: Miyase
authors.initials: M
authors.lastname: Bayraktar
mesh_terms: D000328:Adult; D002097:C-Reactive Protein / Q000378:metabolism*; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000097:blood* / Q000188:drug therapy*; D052243:Resistin / Q000097:blood*; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000627:therapeutic use*; D014284:Triiodothyronine / Q000097:blood
chemical_list: D052243:Resistin; D014284:Triiodothyronine; D013972:Thyrotropin; D002097:C-Reactive Protein; D013974:Thyroxine